Lazard Asset Management’s XBiotech XBIT Stock Holding History

Lazard Asset Management’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-388	Closed	-$7K	–	2005
2020 Q3	$7K	Buy	+388	New	+$6.7K	﹤0.01%	1521

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Lazard Asset Management's XBIT Position: Q4 2020 in Review

Lazard Asset Management sold out of XBiotech (XBIT) in Q4 2020, closing a stake of 388 shares — an estimated $7K sold.

Lazard Asset Management first reported a position in XBIT in Q3 2020 and held it in 1 quarter. The position peaked at $7K in Q3 2020. 66 funds tracked by Wall St. Rank hold XBIT as of Q4 2020.

Lazard Asset Management reported no remaining XBiotech position as of Q4 2020 after selling out during the quarter.
Lazard Asset Management sold 388 XBiotech shares in Q4 2020, an estimated $7K.
Lazard Asset Management first reported a position in XBiotech in Q3 2020 and held it in 1 quarter.
Lazard Asset Management's XBiotech position peaked at $7K in Q3 2020.
66 funds tracked by Wall St. Rank held XBiotech as of Q4 2020.

Based on Lazard Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.